Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CTSH | P09668 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | CALCR | P30988 | 8/20 | 0.42 |
| ▸ | RAMP3 | O60896 | 6/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31124516 | 0.84 | F2 (0.46) | F2OPRM1OPRD1 | |
| SCHEMBL31124515 | 0.84 | F2 (0.46) | F2OPRM1OPRD1 | |
| SCHEMBL29898879 | 0.84 | C5AR1 (0.53) | F2CALCRRAMP3C5AR1 | |
| SCHEMBL29684071 | 0.83 | OPRD1 (0.38) | OPRM1OPRD1 | |
| SCHEMBL29641693 | 0.82 | SLC6A2 (0.48) | F2CALCRRAMP3C5AR1 | |
| SCHEMBL29384601 | 0.81 | SLC6A2 (0.52) | F2CALCRRAMP3 | |
| SCHEMBL30254127 | 0.81 | CALCRL (0.47) | ITGB3ITGAVOPRM1OPRD1C5AR1 | |
| SCHEMBL29641566 | 0.81 | OPRM1 (0.43) | F2OPRM1OPRD1 | |
| SCHEMBL15685981 | 0.81 | CTSL (0.48) | CTSLCTSSCTSKCTSHCALCR | |
| SCHEMBL30253903 | 0.81 | SLC6A2 (0.51) | OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254186-A1 | GLP-1 Receptor Agonists Having Improved Pharmacological and Drug Delivery Properties | DARBIX LLC | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254186-A1 | GLP-1 Receptor Agonists Having Improved Pharmacological and Drug Delivery Properties | GLP1R, GIPR, IAPP | F2 4191/4885CTSL 2221/4885CTSS 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.